Friday, 20 Apr 2018

You are here

CALM Study: Tight Control with Anti-TNF Wins in Crohn's Disease

Not unlike rheumatoid arthritis and other inflammatory disorders, therapeutic efficacy in Crohn's disease (CD) is often assessed clinically. There is growing use and interest in biomarkers of intestinal inflammation, such as faecal calprotectin and C-reactive protein. But Lancet has now reported a clinical trial has shown that a tight control strategy can yield better responses to TNF inhibitors when compared to usual care. 

The CALM study was multicenter, open-label, randomised, controlled phase 3 study, in adults with active endoscopic Crohn's disease (Crohn's Disease Endoscopic Index of Severity [CDEIS] >6 and a Crohn's Disease Activity Index (CDAI) of 150–450 in patients who were DMARD and biologic naive.

Patients were randomized 1:1 ratio to either tight control or clinical management groups. After 8 weeks of prednisone induction therapy, treatment was escalated in a stepwise manner, from adalimumab induction followed by adalimumab every other week, adalimumab every week, and lastly to both weekly adalimumab and daily azathioprine.

The primary endpoint was mucosal healing (CDEIS <4) with absence of deep ulcers 48 weeks after randomisation. 

Dose escalation was different between groups. The Tight Control group used mulitiple definitions of failure (fecal calprotectin ≥250 μg/g, C-reactive protein ≥5mg/L, CDAI ≥150, or prednisone use), while the clinical management group only used changes in the CDAI or prednisone use.

A total of  244 patients were enrolled w/ a mean disease duration < 1 year. Significantly more Tight Control patients achieved the primary endpoint at week 48 (46%) compared to those with usual care (30%) (p=0·010).

There were no unexpected adverse events which were balanced between groups; and there were no treatment-related deaths. Dropouts were equal between groups (24-26%), mostly due to adverse events.

CALM is the first study to show that timely escalation, using an advanced tight control strategy, can lead to clinical and endoscopic outcomes than symptom-driven decisions alone. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Favorable Certolizumab Safety Profile in Pregnancy

Clowse and colleagues have published an extensive review of the certolizumab pegol (CZP) in pregnancy database, and found no evidence that CZP has a teratogenic effect or contributes to fetal harm when compared to the general population. 

Severe Stevens-Johnson and Toxic Epidermal Necrolysis Syndromes May Respond to Etanercept

The Journal of Clinical Investigation reports the results of a trial wherein etanercept (ETN) was shown to be effective in treating cytotoxic T lymphocyte–mediated (CTL-mediated) severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).

Pediatric Use of TNF inhbitors Does Not Increase Malignancy Risk

A study of USA administrative claims data between 2000 to 2014 assessed the risk of cancer with exposure to tumour necrosis factor inhibitor (TNFi) in pediatric patients and found that TNFi therapy did not significantly increase the risk compared those not receiving TNFi.

Obesity Outweighs Psoriasis in Comorbidity Risk with Children

Like their adult counterparts, psoriasis in children is an independent risk factor for comorbidity, but not as much as  obesity.

Using claims data from Optum Laboratories Data Warehouse (150 million privately insured and Medicare enrollees), of 29 957 children with psoriasis were matched with a comparator cohort (children without psoriasis) and studied for the effects of psoriasis and obsesity. 

Anti-Drug Antibodies Partly Explain Secondary TNF Inhibitor Failures

An observational study of patients with active rheumatoid arthritis (RA) or spondyloarthritis (SpA) experiencing secondary failure to TNF inhibitor (TNFi) therapy showed that (secondary) loss of efficacy to a TNFi was associated with anti-drug antibodies in less than 30% of patients.